92721-94-3

Basic information

• Product Name: 1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine
• Synonyms: 1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine
• CAS NO: 92721-94-3
• Molecular Formula: C₁₁H₁₃N₃O
• Molecular Weight: 203.24042
• Mol File: 92721-94-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine(92721-94-3)
• EPA Substance Registry System: 1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-amine(92721-94-3)

Safety Data

• Hazardous Substances Data: 92721-94-3(Hazardous Substances Data)

Usage

Class

Pyrazole compounds

Common uses

Pharmaceutical and agrochemical industries

Structural features

a. Pyrazole derivative
b. Methoxyphenyl group attached
c. Methyl group attached to the pyrazole ring

Potential applications

Development of new drugs and agrochemical products

Research status

Further research and testing required to understand potential applications and effects

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 39232-91-2 m-methoxyphenylhydrazine hydrochloride 
• 763-33-7 (E)-3-aminocrotononitrile 
• 15384-39-1 (3-methoxyphenyl)hydrazine 

Downstream Products

• 1027192-08-0 2-{[2-(3-methoxy-phenyl)-5-methyl-2H-pyrazol-3-ylamino]-methylene}-malonic acid diethyl ester 
• 1027371-37-4 4-chloro-1-(3-methoxy-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 1026151-85-8 4-chloro-1-(3-methoxy-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 851521-21-6 4-chloro-1-(3-methoxy-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide 
• 1027521-04-5 4-chloro-1-(3-methoxy-phenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 

Relevant articles and documents

Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists

Nonstructural protein 1 (NS1) plays a crucial function in the replication, spread, and pathogenesis of influenza virus by inhibiting the host innate immune response. Here we report the discovery and optimization of novel pyrazolopyridine NS1 antagonists that can potently inhibit influenza A/PR/8/34 replication in MDCK cells, rescue MDCK cells from cytopathic effects of seasonal influenza A strains, reverse NS1-dependent inhibition of IFN-β gene expression, and suppress the slow growth phenotype in NS1-expressing yeast. These pyrazolopyridines will enable researchers to investigate NS1 function during infection and how antagonists can be utilized in the next generation of treatments for influenza infection.

PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.